OTHER INFORMATION
−Removed: 2021 Corporate Performance Goals
−Removed: On October 29, 2021, the Compensation Committee approved corporate performance goals for the fiscal year ending December 31, 2021.
−Removed: The corporate performance goals, which may be updated at the Board’s discretion during 2021, include:
−Removed: goals related to executing our development plan for rNAPc2 (AB201), our clinical product candidate for the treatment of patients with COVID-19;
−Removed: goals related to further defining our development plan for Gencaro, our clinical product candidate for the treatment of atrial fibrillation;
−Removed: finance and corporate compliance goals.
+Added: Item 5.08 Shareholder Director Nominations
+Added: On May 2, 2022, the Company determined that it anticipates that the date of its 2022 annual stockholder meeting will be more than 30 calendar days after the date of the Company’s 2021 annual stockholder meeting, but has not made a final determination as to such date.
+Added: Once available, the Company will file an amendment to this report or file a Current Report on Form 8-K to (i) announce the date of the Company’s 2022 annual stockholder meeting;
+Added: and (ii) to disclose the date by which a nominating stockholder or nominating stockholder group must submit a notice on Schedule 14N, which date shall be a reasonable time before the Company mails its proxy materials for its 2022 annual stockholder meeting
EXHIBIT INDEX
28 unchanged sentences
(Principal Financial and Accounting Officer)
−Removed: November 2, 2021
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.